Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress.

Przetocka S, Porro A, Bolck HA, Walker C, Lezaja A, Trenner A, von Aesch C, Himmels SF, D'Andrea AD, Ceccaldi R, Altmeyer M, Sartori AA.

Mol Cell. 2018 Nov 1;72(3):568-582.e6. doi: 10.1016/j.molcel.2018.09.014. Epub 2018 Oct 18.

PMID:
30344097
2.

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.

Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.

PMID:
29035360
3.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, d'Enghien CD, Bluteau O, Cuccuini W, Gachet S, de Latour RP, Leblanc T, Socié G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J.

J Clin Invest. 2017 Mar 1;127(3):1117. doi: 10.1172/JCI92946. Epub 2017 Mar 1. No abstract available.

4.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, Dubois d'Enghien C, Bluteau O, Cuccuini W, Gachet S, Peffault de Latour R, Leblanc T, Socié G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J.

J Clin Invest. 2016 Sep 1;126(9):3580-4. doi: 10.1172/JCI88010. Epub 2016 Aug 8. Erratum in: J Clin Invest. 2017 Mar 1;127(3):1117.

5.

FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.

Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea AD, Ceccaldi R.

Cell Rep. 2016 Jun 14;15(11):2488-99. doi: 10.1016/j.celrep.2016.05.031. Epub 2016 Jun 2.

6.

The Fanconi anaemia pathway: new players and new functions.

Ceccaldi R, Sarangi P, D'Andrea AD.

Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49. doi: 10.1038/nrm.2016.48. Epub 2016 May 5. Review.

PMID:
27145721
7.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.

Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. Review.

8.

Repair Pathway Choices and Consequences at the Double-Strand Break.

Ceccaldi R, Rondinelli B, D'Andrea AD.

Trends Cell Biol. 2016 Jan;26(1):52-64. doi: 10.1016/j.tcb.2015.07.009. Epub 2015 Oct 1. Review.

9.

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, O'Connor KW, Konstantinopoulos PA, Elledge SJ, Boulton SJ, Yusufzai T, D'Andrea AD.

Nature. 2015 Feb 12;518(7538):258-62. doi: 10.1038/nature14184. Epub 2015 Feb 2.

10.

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.

Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.

11.

Transcriptional repressor ZBTB1 promotes chromatin remodeling and translesion DNA synthesis.

Kim H, Dejsuphong D, Adelmant G, Ceccaldi R, Yang K, Marto JA, D'Andrea AD.

Mol Cell. 2014 Apr 10;54(1):107-118. doi: 10.1016/j.molcel.2014.02.017. Epub 2014 Mar 20.

12.

A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Lecourt S, Mouly E, Freida D, Cras A, Ceccaldi R, Heraoui D, Chomienne C, Marolleau JP, Arnulf B, Porcher R, Caillaud C, Vanneaux V, Belmatoug N, Larghero J.

PLoS One. 2013 Jul 25;8(7):e69293. doi: 10.1371/journal.pone.0069293. Print 2013.

13.

Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, Pla M, Vasquez N, Zhang QS, Pondarre C, Peffault de Latour R, Gluckman E, Cavazzana-Calvo M, Leblanc T, Larghero J, Grompe M, Socié G, D'Andrea AD, Soulier J.

Cell Stem Cell. 2012 Jul 6;11(1):36-49. doi: 10.1016/j.stem.2012.05.013. Epub 2012 Jun 7.

14.

Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass.

Jouan J, Golmard L, Benhamouda N, Durrleman N, Golmard JL, Ceccaldi R, Trinquart L, Fabiani JN, Tartour E, Jeunemaitre X, Menasché P.

J Thorac Cardiovasc Surg. 2012 Aug;144(2):467-73, 473.e1-2. doi: 10.1016/j.jtcvs.2011.12.022. Epub 2012 Jan 20.

15.

Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.

Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pagès MP, Vasquez N, Dubois d'Enghien C, Larghero J, Peffault de Latour R, Rocha V, Dalle JH, Schneider P, Michallet M, Michel G, Baruchel A, Sigaux F, Gluckman E, Leblanc T, Stoppa-Lyonnet D, Preudhomme C, Socié G, Soulier J.

Blood. 2011 Apr 14;117(15):e161-70. doi: 10.1182/blood-2010-09-308726. Epub 2011 Feb 16.

16.

Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Ceccaldi R, Briot D, Larghero J, Vasquez N, Dubois d'Enghien C, Chamousset D, Noguera ME, Waisfisz Q, Hermine O, Pondarre C, Leblanc T, Gluckman E, Joenje H, Stoppa-Lyonnet D, Socié G, Soulier J.

J Clin Invest. 2011 Jan;121(1):184-94. doi: 10.1172/JCI43836. Epub 2010 Dec 22.

Supplemental Content

Loading ...
Support Center